Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of TAR-210 versus intravesical single-agent chemotherapy in FGFR-altered intermediate-risk NMIBC
CTR20242467Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Erda-iDRS in bladder cancer, non-muscle-invasive bladder cancer (NMIBC), sponsored by Janssen Pharmaceutical. Started Sep 2024; status: active.
02
Drugs
Erda-iDRS
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on CTR20242467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242467.